Global Point of Care Diagnostics/Testing Market Size, Share & Trends Analysis Report, 2019-2025 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Point
of Care Diagnostics/Testing Market Size, Share & Trends Analysis Report
by Product (Glucose, Blood Gas/Electrolytes, Cancer Marker), By End Use
(Clinic, Hospital), And Segment Forecasts, 2019 – 2025”
report
has been added to ResearchAndMarkets.com’s offering.

The global point of care testing market size is expected to reach USD
22.8 billion by 2025, at a CAGR of 3.3%

The ability of Point of Care (POC) tests to render rapid and accurate
results to promote patient-centered healthcare at bedside settings as
well as in the remote areas results in higher penetration of POC devices
and solutions.

Adaptation of automated laboratory systems and highly integrated
solutions facilitate the diagnostic workflow, which in turn drives
adoption of point of care diagnostic/testing products. Lack of skilled
professionals or medical personnel with limited training especially in
diagnostics can also easily use these devices.

Rise in R&D activities among key players to introduce novel POC tests
and devices for rapid disease detection and monitoring is expected to
fuel industrial progression. Recently, in February 2018, Siemens
Healthineers received a Food and Drug Administration (FDA) approval for
its Total Carbon Dioxide (TCO2) and Blood Urea Nitrogen (BUN) POC tests,
thereby enhancing its market presence.

Moreover, high prevalence of chronic disorders and cancer results in
large customer base adopting cost-effective and immediate diagnostic
tests, propelling the point of care diagnostics/testing market. This is
further supplemented by numerous favorable initiatives to promote the
employment of POC tests in diagnosis and screening procedures.

Further key findings from the report suggest:

  • Glucose testing held the maximum revenue share in 2018 due to high
    prevalence of diabetes and introduction of a wide variety of glucose
    meters by companies
  • Hb1Ac testing segment is also expected to show similar trends owing to
    high competition among key players while delivering low-cost Hb1Ac
    tests
  • Detection and analysis of circulating tumor cells during cancer
    progression is predicted to drive the cancer marker vertical with the
    fastest penetration rate in the forthcoming years
  • Clinics is estimated to hold the dominant revenue share of the POC
    diagnostic industry in 2018, due to the employment of a wide range of
    POC tests
  • Increasing awareness about decentralized tests among patients has
    resulted in lucrative growth of home-based POC testing
  • U.S. is anticipated to North America owing to the presence of key
    participants with undergoing significant number of research endeavors
    in the country
  • Continuous developments in healthcare sector to introduce novel and
    accurate diagnostic tests exhibit a potential growth of the market in
    Asia Pacific
  • Major participants in the point of care diagnostics market include F.
    Hoffmann-La Roche Ltd.; Danaher Corporation; Abbott Laboratories;
    bioMrieux SA; Instrumentation Laboratory SpA; Nova Biomedical;
    Trividia Health, Inc.; QIAGEN; Becton Dickinson & Company; Sekisui
    Diagnostics LLC; Quidel Corporation; and Siemens Healthcare GmbH
  • Key vendors are undergoing numerous strategic developments such as
    product development, acquisitions, partnerships, and agreements to
    gain greater market share. For instance, in May 2017, Becton,
    Dickinson and Company collaborated with the FIND to develop point of
    care based biomarker test for bacterial infections.

Companies Featured

  • F. Hoffmann-La Roche Ltd.
  • Abbott Laboratories
  • Siemens Healthcare GmBH
  • Danaher Corporation
  • bioMerieux SA
  • Abaxis, Inc.
  • Becton Dickinson & Company
  • Qiagen N.V.
  • Spectral Diagnostics
  • Instrumentation Laboratory SpA
  • Johnson and Johnson
  • Nova Biomedical
  • Nipro Diagnostics Inc
  • HemoCue AB
  • International Technidyne Corporation (ITC)
  • Quidel Corporation
  • Trinity Biotech PLC
  • Sekisui Diagnostics LLC
  • OraSure Technologies Inc

For more information about this report visit https://www.researchandmarkets.com/r/fv6lic

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Point-of-Care
Diagnostics